ASX - Delayed Quote AUD

Immuron Limited (IMC.AX)

0.0820

0.0000

(0.00%)

At close: January 10 at 3:23:54 PM GMT+11

UPDATE: Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Small Cap Growth Virtual Investor Conference, held December 5th are now available for online viewing. REGISTER NOW AT: https://bit.ly/49lNzqK The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts ma

GlobeNewswire last month

XBOTF

NEXNF

MHGU
Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Small Cap Growth Virtual Investor Conference to be held December 5th. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/49lNzqK It is recommended that investors pre-register and ru

GlobeNewswire last month

BNAI

BNAIW

XBOTF
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit Virtual Conference presentations are now available for on-demand viewing. Participants and those ...

ACCESSWIRE last month

LMFA

CPSH

PLUR
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com on Thursday 5th December 2024 (2.30pm U.S. Eastern time). Immuron invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com DATE: December 5thTIME: 2

GlobeNewswire last month

IMRN
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21st Virtual Investor Summit Microcap Event (November 21, US Eastern Time). A copy of the presentation is available on the Company’s website. https://www.immuron.com.au/corporate-presentations/ This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Steven LydeamoreChi

GlobeNewswire last month

IMRN
Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

MELBOURNE, AUSTRALIA / ACCESSWIRE / November 18, 2024 /Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated diseases. The company will be available for 1-on-1 ...

ACCESSWIRE last month

IMRN
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp

GlobeNewswire 2 months ago

VOXR

BVAXF

CIA
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside chat at the Maxim Virtual Healthcare Conference on Wednesday, 16th October 2024 (4.30pm U.S. Eastern time). A copy of the presentation covering information being discussed is available on the Company’s website. https://www.immuron.com.au/corporate-presentations/ This release has been authorised by t

GlobeNewswire 2 months ago

IMRN
Immuron Travelan® continued strong sales growth

Sales Highlights: Global• September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia• September 2024 Quarter AUD$1.0 million up 3% on prior quarter NorthAmerica• September 2024 Quarter AUD$0.5 million up 48% on prior quarter MELBOURNE, Australia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued strong sales growth (unaudited) of Travelan®, an over-the-co

GlobeNewswire 2 months ago

IMRN
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. Following discussion with the US Naval Medical Research Command (NMRC), today the Company can announce that the NMRC has completed the interim analysis for the clinical evaluation of a new oral therapeutic t

GlobeNewswire 3 months ago

IMRN
Immuron Full Year 2024 Earnings: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Immuron ( ASX:IMC ) Full Year 2024 Results Key Financial Results Revenue: AU$4.90m (up 172% from FY 2023). Net loss...

Simply Wall St. 3 months ago

IMRN
Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

MIAMI, Sept. 24, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 75th Emerging Growth Conference on September 25 & 26, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting c

GlobeNewswire 3 months ago

VGZ

AEMD

IMRN
Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 Investigational new drug (IND) application for IMM-529 planned for 1H 2025 MELBOURNE, Australia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical co

GlobeNewswire 4 months ago

IMRN
Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now

MIAMI, Aug. 21, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire 4 months ago

CYIO

SDA

SDAWW
US DoD grants $2.3m to Immuron for military version of anti-diarrhoeal Travelan

The research award will target Campylobacter, Shigella and Enterotoxigenic E coli strains.

Pharmaceutical Technology 4 months ago

IMC.AX
0.00%
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the funding of a new research agreement for the Naval Medical Research Command (NMRC), and Walter Reed Army Institute of Research (WRAIR) Silver Spring, MD, USA. T

GlobeNewswire 4 months ago

IMRN
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on August 22nd, 2024. Immuron Limited invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conf

GlobeNewswire 4 months ago

IMRN
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on: Thursday 8th August 2024, 11:00am Australian Eastern Standard Time (9:00am AWST). Chief Executive Officer, Steven Lydeamore will provide an update on additional data analysis of IMM-124E (Travelan®) Phase 2 trial and next steps. Following the presentation, attendees will have the opportunity to

GlobeNewswire 5 months ago

IMRN
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companie

GlobeNewswire 5 months ago

CVKD

GDTC

CRVO
Immuron announces record Travelan® sales globally, Australia and USA

Sales Highlights: Global• FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) • June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter Australia• FY 2024 AUD$3.7 million up 223% on pcp • June 2024 Quarter AUD$1.0 million up 200% on pcp and 11% on prior quarter USA• FY 2024 Record sales of AUD$1.1 million up 74% on pcp • June 2024 Quarter AUD$0.3 million up 546% on pcp; down 1% on prior quarter Canada• FY2024 AUD$0.1 million up 6637% on pcp MELBOURNE, Australia, Ju

GlobeNewswire 5 months ago

IMRN

Performance Overview

Return	IMC.AX	S&P/ASX 200 [XJO]
YTD	+3.80%	+1.65%
1-Year	+7.89%	+11.05%
3-Year	-14.58%	+11.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Immuron Limited (IMC.AX)

UPDATE: Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

Immuron Travelan® continued strong sales growth

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Immuron Full Year 2024 Earnings: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now

US DoD grants $2.3m to Immuron for military version of anti-diarrhoeal Travelan

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

Immuron announces record Travelan® sales globally, Australia and USA

Performance Overview